|
| 36467065 | Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China. | Frontiers in Pharmacology | 2022 |
| 34418665 | First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial. | European Journal of Cancer | 2021 |
| 30683736 | Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer. | J Exp Med | 2019 |
| 29496049 | STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV status in head and neck cancer. | Oral Oncology | 2018 |
| 30419840 | Analysis of oncogenic activities of protein kinase D1 in head and neck squamous cell carcinoma. | BMC Cancer | 2018 |
| 28559019 | IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer. | Oral Oncol | 2017 |
| 26619122 | Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. | J Clin Invest | 2016 |
| 27339168 | Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane. | Cancer Prev Res (Phila) | 2016 |
| 27267892 | STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma. | Cancer Prev Res (Phila) | 2016 |
| 26992898 | Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma. | Carcinogenesis | 2016 |
| 27035818 | Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. | J Clin Invest | 2016 |
| 25982282 | Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer. | Oncogene | 2016 |
| 26181029 | Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. | JAMA Oncol | 2015 |
| 25658924 | Challenges in EGFRvIII detection in head and neck squamous cell carcinoma. | PLoS One | 2015 |
| 25972070 | STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients. | Cancer Immunol Res | 2015 |
| 26138066 | Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies. | Clin Cancer Res | 2015 |
| 25107914 | Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303. | Clin Cancer Res | 2014 |
| 24395800 | Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. | Proc Natl Acad Sci U S A | 2014 |
| 24395569 | Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects. | Mol Med | 2014 |
| 24727329 | Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. | Clin Cancer Res | 2014 |
| 25127378 | Quantifying metabolic heterogeneity in head and neck tumors in real time: 2-DG uptake is highest in hypoxic tumor regions. | PLoS One | 2014 |
| 25061874 | EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. | J Clin Invest | 2014 |
| 24692084 | Choline phosphate cytidylyltransferase-α is a novel antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomas. | Cancer | 2014 |
| 23363816 | SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. | Clin Cancer Res | 2013 |
| 23645351 | Expression of EGFR, VEGF, and NOTCH1 suggest differences in tumor angiogenesis in HPV-positive and HPV-negative head and neck squamous cell carcinoma. | Head Neck Pathol | 2013 |
| 22158872 | Chemokine receptor 7 (CCR7) gene expression is regulated by NF-κB and activator protein 1 (AP1) in metastatic squamous cell carcinoma of head and neck (SCCHN). | J Biol Chem | 2012 |
| 22351687 | Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. | Clin Cancer Res | 2012 |
| 22825581 | Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. | Clin Cancer Res | 2012 |
| 22719020 | First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. | Cancer Discov | 2012 |
| 23226094 | Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models. | Neoplasia | 2012 |
| 21881918 | Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies. | Invest New Drugs | 2012 |
| 21737503 | XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. | Clin Cancer Res | 2011 |
| 21798893 | The mutational landscape of head and neck squamous cell carcinoma. | Science | 2011 |
| 21889392 | Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. | Oral Oncol | 2011 |
| 21363880 | Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. | Ann Oncol | 2011 |
| 21079141 | Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. | J Clin Oncol | 2010 |